You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

osimertinib

( OH sim ER ti nib )
Funding:
Exceptional Access Program
  • Osimertinib - Second-line monotherapy of patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer, according to specific criteria
Other Name(s): Tagrisso ()
Appearance: tablet in various strengths, shapes and colours

You might also be interested in